We are live on ! Find out more
AKRO

Akero Therapeutics
AKRO

Delisted

AKRO was delisted on the 8th of December, 2025.

Back to rankings

57 hedge funds and large institutions have $422M invested in Akero Therapeutics in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 3

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

100% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 12

46% more capital invested

Capital invested by funds: $288M → $422M (+$133M)

21.91% more ownership

Funds ownership: 44.62% → 66.53% (+22%)

6% more funds holding

Funds holding: 54 → 57 (+3)

Holders
57
Holders Change
+3
Holders Change %
+5.56%
% of All Funds
1.12%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
11
Increased
24
Reduced
12
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$7.85M
2
BlackRock
BlackRock
New York
+$4.8M
3
HA
HHLR Advisors
Cayman Islands
+$2.93M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.47M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.07M

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$2.96M
2
Millennium Management
Millennium Management
New York
-$1.67M
3
Alkeon Capital Management
Alkeon Capital Management
New York
-$1.31M
4
OAM
Oxford Asset Management
United Kingdom
-$1.14M
5
HSBC Holdings
HSBC Holdings
United Kingdom
-$615K
Name Holding Trade Value Shares
Change 		Change in
Stake
Ensign Peak Advisors
26
Ensign Peak Advisors
Utah
$529K +$493K +23,823 New
Citadel Advisors
27
Citadel Advisors
Florida
$459K -$52.1K -2,517 -11%
CS
28
Candriam SCA
Luxembourg
$444K – – –
VEA
29
Virtus ETF Advisers
New York
$433K +$404K +19,531 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$421K +$166K +8,001 +73%
OAM
31
Oxford Asset Management
United Kingdom
$353K -$1.14M -54,994 -78%
Bank of Montreal
32
Bank of Montreal
Ontario, Canada
$236K +$4.28K +207 +2%
PMAM
33
Penn Mutual Asset Management
Pennsylvania
$231K +$215K +10,409 New
TD Asset Management
34
TD Asset Management
Ontario, Canada
$229K – – –
BFM
35
Boothbay Fund Management
New York
$222K +$207K +10,000 New
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$165K – – –
Morgan Stanley
37
Morgan Stanley
New York
$148K +$104K +5,003 +301%
Bank of America
38
Bank of America
North Carolina
$132K +$82.7K +3,997 +204%
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$118K – – –
Barclays
40
Barclays
United Kingdom
$112K +$48.8K +2,361 +89%
UBS Group
41
UBS Group
Switzerland
$72K -$58.9K -2,847 -47%
Citigroup
42
Citigroup
New York
$71K +$61.6K +2,976 +1,410%
Wells Fargo
43
Wells Fargo
California
$70K +$57.5K +2,778 +720%
AIG
44
American International Group
New York
$68K +$910 +44 +1%
TRCT
45
Tower Research Capital (TRC)
New York
$68K +$63.1K +3,049 New
Deutsche Bank
46
Deutsche Bank
Germany
$37K +$7.74K +374 +28%
Victory Capital Management
47
Victory Capital Management
Texas
$36K -$21.1K -1,021 -39%
SO
48
STRS Ohio
Ohio
$28K – – –
CSS
49
Cubist Systematic Strategies
Connecticut
$23K -$32.2K -1,554 -60%
Legal & General Group
50
Legal & General Group
United Kingdom
$20K +$3.12K +151 +20%
1
2
3

AKRO Hedge Fund Activity: Q4 2019 in Review

57 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q4 2019, worth a combined $422M — up 46% from $288M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new AKRO positions and 3 closed out — a net gain of 8 holders — while 24 added to existing stakes and 12 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $7.85M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $2.96M sold.

  • 57 institutional investors held Akero Therapeutics (AKRO) as of Q4 2019, up from 54 in Q3 2019.
  • Funds reported $422M of Akero Therapeutics stock for Q4 2019, up 46% quarter-over-quarter.
  • 11 funds opened new Akero Therapeutics positions in Q4 2019 and 3 closed out, a net change of +8 holders.
  • The largest Akero Therapeutics buyer in Q4 2019 was Janus Henderson Group, an estimated $7.85M added.
  • The largest Akero Therapeutics seller in Q4 2019 was Sphera Funds Management, an estimated $2.96M sold.

Based on aggregated 13F filings for Q4 2019.